Literature DB >> 10505286

[Therapy of acute myocardial infarct--primary PTCA or thrombolysis?].

A Vogt1, K L Neuhaus.   

Abstract

Since reperfusion of the infarct-related coronary artery has been established as a mainstay in the treatment of acute myocardial infarction (AMI) mechanical recanalization by direct angioplasty has been used as an alternative to the standard treatment with thrombolysis. Direct PTCA is more efficient than thrombolysis in terms of reperfusion rates, whereas thrombolysis is more readily available. Thrombolysis reduces mortality from AMI by approximately 25%. The clinical efficacy is strongly time-dependent, and treatment within the first hour of AMI improves survival by nearly 50% by preventing transmural infarction in a significant proportion of the patients. The disadvantage of thrombolysis is its limited efficacy in terms of rapid, complete and sustained patency of the infarct vessel yielding optimal results in only 50% of the patients. Direct PTCA is generally agreed to be more efficient to recanalize the infarct vessel, but its clinical advantage remains controversial. The first randomized studies of direct PTCA in AMI from highly specialized centers in selected patients reported success rates of coronary reperfusion up to 97% resulting in a trend to less death and reinfarction, but the differences were significant only in a metaanalysis of these small studies. The real world of direct PTCA has been depicted by a large registry in Germany of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) now including more than 4,000 direct PTCA-procedures since 1994. In this registry, the success rate of direct PTCA was 87% as defined by a final TIMI-grade 3 perfusion of the infarct vessel which is close to the data of the MITI-registry and the GUSTO IIb study. Failed PTCA was associated with an exceptionally high mortality rate of 36% confirming earlier observational reports. The non-randomized comparison of thrombolysis and direct PTCA in the MITI-registry showed no differene in survival or reinfarction rates, and the randomized GUSTO IIb substudy of direct PTCA versus front-loaded alteplase showed a small advantage in death and reinfarction rates at 30 days which dissipated over time leaving no significant clinical advantage of direct PTCA over thrombolysis at 6 months. Thus, in myocardial infarction in general the advantage of direct PTCA over thrombolysis is at best minimal. The reason is very probably the longer time lag until the procedure is started, the lower success rate as compared to the first reports of some specialized centers, and the clearly negative impact of failed PTCA on survival. Moreover, the immediate success of direct PTCA seems to be overestimated by the operator as demonstrated by comparison of central and local estimates of the TIMI flow rates in GUSTO IIb. Improvements of direct PTCA in AMI might be possible by coronary stenting which has markedly increased to more than 60% during the last year in the ALKK-registry. This was accompanied by a slight decrease in death and reinfarction rates. Further improvements can be expected from GP IIb/IIIa platelet antagonists which are under clinical investigation. It has been claimed, that in cardiogenic shock direct PTCA is more effective than thrombolysis. This hypothesis is based on comparison of failed versus successful PTCA-attempts, but this comparison is not valid since failed procedures clearly increase mortality. In the GUSTO-1 study patients with cardiogenic shock had lower mortality with than without an early coronary angiogram. This survival advantage, however, was independent of revascularization since only half of the patients with an early angiogram had PTCA. The same was observed in the International Shock Registry, reflecting significant selection bias in that patients in relatively better condition will be taken to the cathlab whereas apparently hopeless cases will not. In the ALKK-registry half of the patients in cardiogenic shock died after direct PTCA casting doubt on the presumed high clinical efficacy of this strategy. (ABST

Entities:  

Mesh:

Year:  1999        PMID: 10505286     DOI: 10.1007/BF03043927

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  38 in total

1.  Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long-term survival.

Authors:  L Lee; R Erbel; T M Brown; N Laufer; J Meyer; W W O'Neill
Journal:  J Am Coll Cardiol       Date:  1991-03-01       Impact factor: 24.094

2.  Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-08-05       Impact factor: 91.245

3.  Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial.

Authors:  W D Weaver; M Cerqueira; A P Hallstrom; P E Litwin; J S Martin; P J Kudenchuk; M Eisenberg
Journal:  JAMA       Date:  1993-09-08       Impact factor: 56.272

4.  A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group.

Authors:  C L Grines; K F Browne; J Marco; D Rothbaum; G W Stone; J O'Keefe; P Overlie; B Donohue; N Chelliah; G C Timmis
Journal:  N Engl J Med       Date:  1993-03-11       Impact factor: 91.245

5.  Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups.

Authors:  R J Gibbons; D R Holmes; G S Reeder; K R Bailey; M R Hopfenspirger; B J Gersh
Journal:  N Engl J Med       Date:  1993-03-11       Impact factor: 91.245

6.  Limitation of infarct size and preservation of left ventricular function after primary coronary angioplasty compared with intravenous streptokinase in acute myocardial infarction.

Authors:  M J de Boer; H Suryapranata; J C Hoorntje; S Reiffers; A L Liem; K Miedema; W T Hermens; M J van den Brand; F Zijlstra
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

7.  Direct percutaneous transluminal coronary angioplasty in acute myocardial infarction. Predictors of short-term outcome and the impact of coronary stenting. Study Group of The Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK).

Authors:  A Vogt; W Niederer; C Pfafferott; H J Engel; W Heinrich; W Merx; J Jehle; K L Neuhaus
Journal:  Eur Heart J       Date:  1998-06       Impact factor: 29.983

8.  Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators.

Authors:  J S Hochman; J Boland; L A Sleeper; M Porway; J Brinker; J Col; A Jacobs; J Slater; D Miller; H Wasserman
Journal:  Circulation       Date:  1995-02-01       Impact factor: 29.690

9.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

10.  Predictors of success for coronary angioplasty performed for acute myocardial infarction.

Authors:  S G Ellis; E J Topol; L Gallison; C L Grines; A B Langburd; E R Bates; J A Walton; W W O'Neill
Journal:  J Am Coll Cardiol       Date:  1988-12       Impact factor: 24.094

View more
  1 in total

Review 1.  [Reperfusion therapy and mechanical circulatory support in patients in cardiogenic shock].

Authors:  K H Scholz
Journal:  Herz       Date:  1999-10       Impact factor: 1.443

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.